RFXANK

Across TCGA pan-cancer cohorts, RFXANK mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RFXANK data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RFXANK mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RFXANK expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where RFXANK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.950	0.742	<.001	53	view →
CCRCC	OS	Median	II,III,IV	1.000	0.373	.006	21	view →
LSCC	DFS	Median	All	0.599	0.790	.015	15	view →
PDAC	DFS	Quartile	III,IV	0.639	0.257	.006	7	view →
HNSC	OS	Median	All	0.347	0.887	.046	4	view →
UCEC	DFS	Median	II,III,IV	0.826	1.000	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RFXANK–LUAD (OS)

Open the LUAD breakdown →